Who Should Avoid Melatonin?

Melatonin is one of the most popular sleep supplements in North America, with use among U.S. adults growing more than fivefold between 1999 and 2018 — and a 2022 Sleep Foundation survey found that over 27% of adults have tried it. For most healthy adults, it is safe and well-tolerated at appropriate doses. But melatonin is a hormone, not a vitamin, and for six specific groups it carries real risks that are worth understanding before you open the bottle.

Table of Contents

1. How Melatonin Works — and Why That Creates Risks for Some People
2. Autoimmune Conditions: The Most Debated Contraindication
3. Drug Interactions: Four Medication Classes That Require Caution
4. Pregnancy and Breastfeeding: Caution, Not Prohibition
5. Children and Adolescents: A Product Quality Problem
6. Older Adults with Dementia: A Formal Clinical Caution
7. Lower Dose, Higher Precision: Why Formulation Matters for Safety
8. Frequently Asked Questions
9. Conclusion
10. Research References

1. How Melatonin Works — and Why That Creates Risks for Some People

Melatonin is a hormone synthesized by the pineal gland in the brain, released in response to darkness to signal that it's time for the body to sleep. It regulates the circadian clock — your body's internal 24-hour timing system — and also plays roles in blood pressure regulation, immune modulation, and antioxidant activity. It is not a sedative in the pharmaceutical sense; it shifts timing, rather than forcing sedation.

These wide-ranging biological functions are exactly what creates risk for specific groups. A supplement that lowers blood pressure slightly at night (generally harmless in healthy adults) can cause unpredictable blood pressure swings in someone on antihypertensives. An immune-modulating hormone that is neutral or beneficial in most people can theoretically aggravate an already overactivated immune system. The hormone reaches multiple tissue types — cardiovascular, immune, neurological, reproductive — and at pharmacological doses (most OTC pills deliver 5–10mg, versus the body's natural 0.1–0.3mg peak), its effects extend well beyond sleep timing.

Understanding which groups face meaningful risk requires looking at each category separately. The evidence is strong for some (drug interactions, dementia falls risk), more uncertain for others (autoimmune, pregnancy), and product-quality-specific for children. In all cases, the practical guidance differs from group to group.

2. Autoimmune Conditions: The Most Debated Contraindication

Melatonin's relationship with the immune system is complex. It generally functions as an immune stimulant — promoting cytokine release and enhancing the activity of certain immune cell types. For people without immune dysfunction, this property is typically neutral or even beneficial. For those with autoimmune conditions, where the immune system already attacks the body's own tissues, adding an immune stimulant carries theoretical risk. Major health institutions including the Mayo Clinic and many European prescribing bodies formally list autoimmune disease as a contraindication.

The evidence, however, is more nuanced than a blanket warning suggests. A 2020 review in the International Journal of Molecular Sciences examined melatonin across multiple autoimmune diseases — multiple sclerosis, lupus, rheumatoid arthritis, type 1 diabetes, and inflammatory bowel disease — and found conflicting results. For some conditions, melatonin appeared beneficial or neutral. For rheumatoid arthritis specifically, a PMC review concluded that some research suggests melatonin may worsen disease activity while other work shows anti-inflammatory effects — the authors called for comprehensive clinical judgment before prescribing. Most practicing sleep physicians report it is "mildly beneficial or basically neutral" for most autoimmune patients in clinical practice.

There is one important exception where the evidence is clearer: myasthenia gravis. A BMC Neurology case series identified 3 patients whose myasthenia gravis worsened within days to weeks of starting melatonin. Two patients did not improve after stopping it, and one required intravenous immunoglobulins after corticosteroids failed. The proposed mechanism is melatonin's upregulation of the adaptive immune system, which directly worsens antibody-mediated neuromuscular dysfunction. For myasthenia gravis specifically, melatonin should be considered contraindicated. For other autoimmune conditions, the practical guidance is: consult your rheumatologist or immunologist first, especially if you are on immunosuppressive therapy.

3. Drug Interactions: Four Medication Classes That Require Caution

Melatonin is metabolized primarily through the liver enzyme CYP1A2, with secondary activity through CYP1A1 and CYP2C19. This metabolic pathway overlaps with numerous common medications, creating the potential for either increased or decreased drug levels — or changes in drug activity — when melatonin is added. The interactions are not uniformly dangerous, but four medication classes require specific attention.

Anticoagulants (blood thinners). Warfarin is the most documented case. In a 10-patient case series at Massachusetts General Hospital, concurrent melatonin and warfarin use produced elevated INR and PT values in most patients — with 6 experiencing possible interaction and 2 experiencing probable interaction. Melatonin has mild antiplatelet properties independently, so the combination may enhance blood-thinning effects beyond what warfarin alone would produce. Anyone on warfarin or other anticoagulants should consult their prescribing physician before starting melatonin, and additional INR monitoring may be warranted.

Anticonvulsants. Mayo Clinic notes that melatonin may inhibit the effects of anticonvulsants and increase seizure frequency, particularly in children with neurological disabilities. This effect appears more pronounced in pediatric populations and in children with pre-existing neurological conditions. Adults with epilepsy on seizure medications should discuss melatonin with their neurologist before use.

Antihypertensives (blood pressure medications). Melatonin has modest blood-pressure-lowering effects in most contexts, but its interaction with antihypertensives is unpredictable. In patients taking the calcium channel blocker nifedipine, 5mg of melatonin for 4 weeks increased systolic blood pressure by 6.5 mmHg and diastolic by 4.5 mmHg — effectively blunting the medication's effectiveness. Blood pressure monitoring after starting melatonin is advisable for those on antihypertensive regimens.

Immunosuppressants. Since melatonin stimulates immune activity, it may directly counteract medications designed to suppress the immune system — including tacrolimus, cyclosporine, and mycophenolate used in organ transplant patients and autoimmune disease management. The Mayo Clinic lists this as a formal interaction. Anyone on immunosuppressive therapy should treat melatonin as potentially incompatible with their regimen and seek physician guidance before use.

4. Pregnancy and Breastfeeding: Caution, Not Prohibition

Melatonin crosses the placenta and is naturally present in breast milk — in fact, melatonin levels are highest in the third trimester of pregnancy, suggesting it plays a physiological role in fetal development. Despite this, exogenous supplementation during pregnancy and breastfeeding is not well studied in humans. Concerns about safety came largely from animal studies, but the translation to humans appears more nuanced.

A 2022 scoping review of 15 human studies on melatonin use during pregnancy and breastfeeding concluded that, contrary to animal data, human evidence does not suggest major safety concerns. Clinical trials using melatonin during pregnancy for other conditions (preeclampsia, preterm labor) did not report significant adverse events. That said, no randomized controlled trials have examined melatonin specifically for insomnia during pregnancy, which means there is no formal evidence base to guide use as a sleep aid in this context.

During breastfeeding, melatonin passes into milk. The NIH LactMed database notes that doses higher than those transferred through breast milk have been used safely in infants directly, and considers low-dose short-term use unlikely to cause harm. However, one case report documented an infant with bleeding issues while the mother was taking a melatonin-plus-valerian supplement — suggesting combination products carry more risk than melatonin alone. The practical position for pregnant and breastfeeding individuals: the evidence does not justify a hard prohibition, but the lack of RCT data means physician guidance is appropriate before use.

5. Children and Adolescents: A Product Quality Problem

Pediatric melatonin use has surged dramatically. Between 2012 and 2021, the number of pediatric melatonin ingestion cases reported to U.S. poison control centers increased 530% — though 84.4% of those cases were asymptomatic. OTC melatonin sales for the broader market grew from $285 million in 2016 to $821 million in 2020, with parents among the primary purchasers for household use. Half of parents in one survey started melatonin for their child without any medical professional's recommendation.

The concern for children is less about melatonin itself and more about the product quality problem in unregulated supplements. The American Academy of Sleep Medicine issued a formal health advisory noting that OTC melatonin content ranges from −83% to +478% of the labeled amount, with the greatest variability found in chewable and gummy formats — precisely the forms most commonly used for children. More seriously, 26% of tested supplements contained undisclosed serotonin at levels from 1 to 75 micrograms. Serotonin is a prescription substance in many jurisdictions, and even at low levels it can trigger serious reactions — including serotonin syndrome — when combined with common medications such as SSRIs, triptans, or ondansetron.

Long-term safety data in children are also lacking. Animal studies have raised questions about potential effects on pubertal timing, though human data have not confirmed this risk. A 2023 systematic review found that children using melatonin are likely to experience non-serious adverse events, but the full extent of short-term and long-term consequences remains uncertain. The AASM and the American Academy of Pediatrics advise physician consultation before use in children — and for children under 2, melatonin is not recommended. The key issue for any family considering melatonin for a child is product selection: pharmaceutical-grade or third-party-tested products with verified content are substantially safer than standard retail gummies.

6. Older Adults with Dementia: A Formal Clinical Caution

Melatonin production declines naturally with age — adults over 65 produce substantially less than younger adults — which is one reason sleep disruption is so prevalent in older populations. Approximately 12–20% of adults over 65 meet criteria for insomnia, and sleep-wake cycle disruption is common in dementia. This makes melatonin a seemingly logical intervention. The clinical picture, however, is more complicated.

For older adults without dementia, the evidence for melatonin is modestly positive. A review of 37 randomized controlled trials found that the most common adverse effects — daytime drowsiness (1.66%) and headache (0.7%) — were minor and brief. Blood pressure monitoring is advisable, particularly for those on antihypertensives, as the combination can produce unpredictable changes. Low doses (0.5mg–1mg) with careful timing appear safer than the high doses typically sold in retail supplements.

For older adults with dementia, the picture is more cautionary. The American Academy of Sleep Medicine's 2015 clinical practice guideline formally recommends against melatonin for elderly patients with dementia, citing increased risk of falls and adverse events that outweigh the limited and inconsistent evidence for sleep benefit. Multiple meta-analyses have found mixed results on sleep improvement in dementia, with no reliable cognitive benefit. The concern is not that melatonin directly harms cognition, but that sedation-related fall risk in this population — who are already at elevated risk — adds meaningful harm without proportionate benefit. If sleep disruption in a dementia patient is a significant care challenge, behavioral interventions and physician-guided options are preferable first steps.

7. Lower Dose, Higher Precision: Why Formulation Matters for Safety

One of the most clinically relevant points in this article is also the most overlooked: most of the risks associated with melatonin in the research literature involve the high doses found in typical retail supplements — 5mg, 10mg, even higher. The body's natural peak melatonin is approximately 0.1–0.3mg. Pharmacological doses of 5–10mg flood the system, produce receptor saturation well beyond what is needed for sleep onset signaling, and are far more likely to produce drug-interaction effects and systemic side effects than the lower doses shown to be effective in clinical studies.

This is where BioAbsorb Nutraceuticals' Liposomal Liquid Melatonin offers a meaningful practical advantage for people who can take melatonin but want to minimize unnecessary exposure. At 1.5mg per full serving — with a graduated dropper that allows dosing in ~0.25mg increments — it enables genuinely low-dose titration that most tablet-based products cannot offer. Standard 5mg or 10mg tablets are fixed doses with no practical way to reduce them. A liquid dropper lets users start at 0.25mg–0.5mg and find the minimum effective dose, which is both the most clinically appropriate and the safest approach.

The liposomal delivery system also matters here. BioAbsorb's formulation achieves 80–95% bioavailability compared to 15–20% for standard tablets, meaning a smaller absolute dose delivers proportionally more active melatonin to the bloodstream. For someone concerned about drug interactions — for example, someone who takes antihypertensives but is not contraindicated for melatonin — achieving effective sleep support at 0.5mg via liposomal delivery is a materially different safety profile than taking 10mg in a poorly-absorbed tablet. The product is GMP-certified, manufactured in a Health Canada-approved Canadian facility, non-GMO, vegan, gluten-free, and every batch is third-party tested with a COA available on request. For people who have cleared melatonin with their physician, precision matters — and $29.99 for 100ml (100 servings) at 1.5mg delivers that at a practical price.

Frequently Asked Questions

Can I take melatonin if I have an autoimmune disease?

It depends on the condition. For most autoimmune diseases, the current evidence suggests melatonin is either mildly beneficial or neutral in clinical practice — but myasthenia gravis is a notable exception where documented exacerbations have been reported. If you have any autoimmune condition and are on immunosuppressive therapy, you should consult your specialist before starting melatonin, as Mayo Clinic notes melatonin can interfere with immunosuppressive therapy. A formal "check with your doctor" is not just a boilerplate disclaimer here — the interaction is real and worth discussing.

Is melatonin safe with blood pressure medication?

Melatonin has a complex and unpredictable interaction with blood pressure medications. In most healthy adults it lowers blood pressure modestly, which could enhance antihypertensive effects. However, with the calcium channel blocker nifedipine specifically, melatonin has been shown to blunt the medication's effectiveness and raise blood pressure by approximately 6.5 mmHg systolic. If you take any antihypertensive, monitoring your blood pressure after starting melatonin and informing your prescriber is advisable.

Should children take melatonin?

For healthy children with simple sleep difficulties, non-pharmacological interventions — consistent sleep schedules, reduced screen time before bed, dark and cool sleep environments — should be tried first. When melatonin is used for children, physician guidance is advisable, children under 2 should not use it, and product selection is critical: most retail gummies have been found to contain inaccurate melatonin levels and some contain undisclosed serotonin. For children with circadian rhythm disorders or neurodevelopmental conditions, melatonin can be an appropriate tool — but under medical supervision with verified products.

Is melatonin safe during pregnancy?

Human evidence to date has not confirmed the safety concerns raised in animal studies, and several clinical trials using melatonin during pregnancy for other conditions did not report major adverse events. However, no randomized controlled trials have studied melatonin specifically for insomnia during pregnancy, meaning there is no formal evidence base to support its routine use in that context. A 2022 scoping review of 15 human studies concluded human evidence suggests melatonin is probably safe, while emphasizing the need for further research. Consulting your OB or midwife before use is the appropriate step.

Why does dose matter so much for safety?

Most of the drug interaction risks and side effects documented in the research involve pharmacological doses of 5–10mg — far above the body's natural peak of 0.1–0.3mg. Clinical studies have found that doses as low as 0.3–0.5mg are effective for circadian entrainment, and that lower doses produce fewer next-day sedation effects. For people who are not strictly contraindicated but have some caution factors (e.g., antihypertensives, mild medications), using the minimum effective dose — ideally through a liquid format that allows precise titration — meaningfully reduces the risk profile compared to a standard retail tablet.

Who is definitely safe to take melatonin?

Healthy adults without the conditions or medications described in this article can generally take melatonin at low doses (0.5–3mg) for short-term sleep support with a well-established safety profile. It is most clearly effective for circadian rhythm issues — jet lag, shift work, and delayed sleep phase — rather than primary insomnia. Adverse effects in large-scale clinical trials were typically minor, brief, and dose-related, making appropriate dosing the most important safety variable for low-risk users.

Conclusion

Melatonin is safe for most healthy adults — that is the clear takeaway from the evidence. But "natural" does not mean universal, and the six groups covered in this article face risks that are real, evidence-based, and worth taking seriously: people with autoimmune conditions (especially myasthenia gravis), those on blood thinners, anticonvulsants, antihypertensives, or immunosuppressants, pregnant and breastfeeding individuals, children given unregulated retail products, and older adults with dementia. If you fall outside these categories and have decided melatonin is right for you, formulation and dose matter — and BioAbsorb Liposomal Liquid Melatonin's graduated dropper and verified-batch manufacturing gives you precision that most retail products cannot match.

Research References

1. Trends in Use of Melatonin Supplements Among US Adults, 1999–2018. JAMA, Vol. 327, No. 5 (2022). Found that melatonin use among U.S. adults increased more than fivefold over two decades, with high-dose use (>5mg/day) also rising, raising concerns about long-term safety in the absence of regulatory oversight.
2. Myasthenia gravis exacerbation after melatonin administration: case series from a tertiary referral centre. BMC Neurology, Vol. 20 (2020). Documented 3 patients with myasthenia gravis who experienced disease worsening within days to weeks of starting melatonin, with one requiring IV immunoglobulins; authors concluded melatonin should be used with caution in this population.
3. Reconsidering the Role of Melatonin in Rheumatoid Arthritis. International Journal of Molecular Sciences, Vol. 21, No. 8 (2020). Reviewed evidence for melatonin in RA, finding conflicting results — some studies showing enhanced inflammatory activity, others showing anti-inflammatory benefit — concluding that clinical rheumatologists must weigh these contradictory effects carefully.
4. Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19. Frontiers in Immunology, PMC (2022). Summarized the Massachusetts General Hospital case series showing INR and PT elevations in 10 patients receiving melatonin and warfarin concurrently, supporting the recommendation for INR monitoring in combined use.
5. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults. Clinical Interventions in Aging, PMC (2023). Documented the nifedipine-melatonin interaction (6.5 mmHg systolic increase), unpredictable blood pressure effects with antihypertensives, and recommended melatonin be treated as a medication rather than a harmless dietary supplement in older adults.
6. Melatonin use during pregnancy and lactation: A scoping review. Brazilian Journal of Psychiatry, Vol. 44 (2022). Reviewed 15 human studies and found that, contrary to animal data, human clinical evidence does not suggest major safety concerns with melatonin use during pregnancy or breastfeeding, while emphasizing the absence of RCT data for insomnia specifically.
7. Melatonin — MotherToBaby Fact Sheet. National Institutes of Health — NCBI (April 2024). Noted melatonin's natural presence in breast milk, the absence of formal safety recommendations for or against use during breastfeeding, and one case report of an infant bleeding issue associated with a melatonin-plus-valerian supplement.
8. Health advisory: melatonin use in children. Journal of Clinical Sleep Medicine, Vol. 19 (2023). American Academy of Sleep Medicine formal advisory documenting −83% to +478% melatonin content variability in OTC supplements, undisclosed serotonin in 26% of products, and a 530% increase in pediatric melatonin ingestions reported to poison control from 2012 to 2021.
9. Melatonin Use in Pediatrics: A Clinical Review on Indications, Multisystem Effects, and Toxicity. Children (MDPI), Vol. 11 (2024). Reviewed pediatric safety data and flagged serotonin contamination (1–75 µg in 8 of tested supplements), melatonin content inaccuracies, and the absence of long-term safety studies in children as key concerns warranting caution.
10. Melatonin — Cognitive Vitality Report. Alzheimer's Drug Discovery Foundation (2023). Summarized the AASM clinical practice guideline recommending against melatonin use in elderly patients with dementia due to elevated fall risk and adverse events, and reviewed mixed evidence for cognitive benefit in this population.
11. The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessment. PMC / EClinicalMedicine (2023). Systematic review of 22 randomized studies with 1,350 pediatric patients finding that children using melatonin are likely to experience non-serious adverse events, and calling for caution and further research given the major gap in long-term safety data.
12. Pediatric Melatonin Ingestions — United States, 2012–2021. MMWR Morbidity and Mortality Weekly Report, Vol. 71, No. 22 (2022). CDC cross-sectional study documenting a 530% increase in pediatric melatonin ingestions reported to U.S. poison control centers between 2012 and 2021, with associated increases in hospitalizations and serious outcomes.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.